Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.
WuXi Biologics and ABL Bio have entered into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies.
AbCellera, a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies, has collaborated with clinical stage biopharmaceutical company Autolus Therapeutics on antibody discovery project.
HOOKIPA Pharma has signed a research collaboration and license agreement with DarwinHealth to develop immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens.
Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.
Roche Group’s member Genentech has agreed to acquire US-based biotechnology firm, Jecure Therapeutics, for an undisclosed sum.
Cyclica has partnered with Bayer to drives drug discovery through artificial intelligence (AI)-augmented integrated network of cloud-based technologies.
Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.
Evotec has entered into a research collaboration with Immuneering on artificial intelligence (AI) driven ligand identification for rare hereditary metabolic diseases.
LEO Pharma and PellePharm have entered into a development and commercialization collaboration to address unmet medical needs in various skin diseases like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.